Tyagi P, Killinger K, McLennan G, Jayabalan N, Chancellor M, Peters KM. Urine chemokine levels correlate with treatment response to phosphodiesterase 4 inhibitor in prostatitis. World J Clin Urol 2017; 6(1): 18-26 [DOI: 10.5410/wjcu.v6.i1.18]
Corresponding Author of This Article
Pradeep Tyagi, PhD, Associate Professor, Department of Urology, University of Pittsburgh School of Medicine, Suite 700 Kaufmann Medical Building, 3471 Fifth Avenue, Pittsburgh, PA 15213, United States. tyagip@upmc.edu
Research Domain of This Article
Urology & Nephrology
Article-Type of This Article
Observational Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Urol. Mar 24, 2017; 6(1): 18-26 Published online Mar 24, 2017. doi: 10.5410/wjcu.v6.i1.18
Urine chemokine levels correlate with treatment response to phosphodiesterase 4 inhibitor in prostatitis
Pradeep Tyagi, Kim Killinger, Gregory McLennan, Nirmal Jayabalan, Michael Chancellor, Kenneth M Peters
Pradeep Tyagi, Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, United States
Kim Killinger, Gregory McLennan, Michael Chancellor, Kenneth M Peters, Oakland University William Beaumont School of Medicine, Beaumont Hospital-Royal Oak, Oakland, MI 48073, United States
Nirmal Jayabalan, School of Material Science and Engineering, Nanyang Technological University, Singapore 639798, Singapore
Author contributions: All the authors contributed to the manuscript.
Institutional review board statement: The study was reviewed and approved by the Human Investigation Committed of Oakland University William Beaumont School of Medicine.
Informed consent statement: All study participants provided informed written consent prior to study enrollment.
Conflict-of-interest statement: None of the authors other than Kenneth Peters have a conflict; Dr. Kenneth M Peters was the investigator of Celgene Sponsored Clinical Trial.
Data sharing statement: No data were created no data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Pradeep Tyagi, PhD, Associate Professor, Department of Urology, University of Pittsburgh School of Medicine, Suite 700 Kaufmann Medical Building, 3471 Fifth Avenue, Pittsburgh, PA 15213, United States. tyagip@upmc.edu
Telephone: +1-412-6924119 Fax: +1-412-6924380
Received: August 12, 2016 Peer-review started: August 16, 2016 First decision: September 28, 2016 Revised: October 27, 2016 Accepted: December 13, 2016 Article in press: December 15, 2016 Published online: March 24, 2017 Processing time: 202 Days and 14.5 Hours
Core Tip
Core tip: Chronic prostatitis or chronic pelvic pain syndrome is a poorly understood and prevalent male condition, which is generally described by pelvic pain in the absence of demonstrable urinary or genital tract infection. Inflammation is considered to play a critical role in the prostatitis and so we carried out a small physician initiated clinical study to investigate the potential efficacy of a new phosphodiesterase 4 inhibitor drug, Apremilast. Urine was collected from the study participants at the baseline and at each visit to assay the chemokine levels and then determine their association with the treatment response. We are the first to report that chemokine levels in urine instead of the semen or prostatic secretions have the potential to serve as non-invasive biomarkers of severity and treatment response of the prostatitis patients.
